PH12020552282A1 - Improvements in immunogenic conjugates - Google Patents
Improvements in immunogenic conjugatesInfo
- Publication number
- PH12020552282A1 PH12020552282A1 PH12020552282A PH12020552282A PH12020552282A1 PH 12020552282 A1 PH12020552282 A1 PH 12020552282A1 PH 12020552282 A PH12020552282 A PH 12020552282A PH 12020552282 A PH12020552282 A PH 12020552282A PH 12020552282 A1 PH12020552282 A1 PH 12020552282A1
- Authority
- PH
- Philippines
- Prior art keywords
- immunogenic conjugates
- carrier polypeptide
- saccharide antigen
- amino acid
- present application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693981P | 2018-07-04 | 2018-07-04 | |
| PCT/US2019/040131 WO2020009993A1 (en) | 2018-07-04 | 2019-07-01 | Improvements in immunogenic conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020552282A1 true PH12020552282A1 (en) | 2021-06-28 |
Family
ID=67439412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020552282A PH12020552282A1 (en) | 2018-07-04 | 2020-12-29 | Improvements in immunogenic conjugates |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP3817775B1 (https=) |
| JP (2) | JP7399934B2 (https=) |
| KR (1) | KR20210042904A (https=) |
| CN (1) | CN112543649B (https=) |
| AU (2) | AU2019299836B2 (https=) |
| BR (1) | BR112020026899A2 (https=) |
| CA (1) | CA3105361A1 (https=) |
| DK (1) | DK3817775T3 (https=) |
| EA (1) | EA202190168A1 (https=) |
| ES (1) | ES2989087T3 (https=) |
| IL (1) | IL279855B2 (https=) |
| MX (1) | MX2020014118A (https=) |
| PH (1) | PH12020552282A1 (https=) |
| SG (1) | SG11202012905PA (https=) |
| WO (1) | WO2020009993A1 (https=) |
| ZA (1) | ZA202100761B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022035816A1 (en) * | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| EP4200268A4 (en) | 2020-08-19 | 2024-10-16 | Vaxcyte, Inc. | CARRIER PROTEIN POLYSACCHARIDE CONJUGATION PROCESS |
| GB202108648D0 (en) * | 2021-06-17 | 2021-08-04 | Inst De Medicina Molecular Joaeo Lobo Antunes | CRM197 protein carrier |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0375778B1 (en) | 1987-06-19 | 1993-09-08 | Terumo Kabushiki Kaisha | Medical instrument and production thereof |
| ATE109008T1 (de) | 1988-02-01 | 1994-08-15 | Praxis Biolog Inc | T-zellen-epitope als träger für einen konjugierten impfstoff. |
| FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
| JP2001190665A (ja) | 2000-01-14 | 2001-07-17 | Terumo Corp | シリンジ |
| WO2001070763A1 (en) * | 2000-03-22 | 2001-09-27 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
| GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA2604363C (en) | 2005-04-08 | 2015-06-16 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| NZ562719A (en) | 2005-04-08 | 2008-12-24 | Wyeth Corp | Separation of contaminants from streptococcus pneumoniae polysaccharide by pH manipulation |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| NZ598367A (en) * | 2005-09-01 | 2013-10-25 | Novartis Vaccines & Diagnostic | Multiple vaccination including serogroup C meningococcus |
| PL1973564T3 (pl) | 2005-12-22 | 2017-04-28 | Glaxosmithkline Biologicals S.A. | Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae |
| WO2007116409A2 (en) * | 2006-04-11 | 2007-10-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Improved vaccines comprising multimeric hsp60 peptide carriers |
| PT2074221E (pt) | 2006-10-10 | 2010-09-06 | Wyeth Llc | Métodos melhorados para a separação de polissacáridos tipo 3 de streptococcus pneumoniae |
| PT2129693T (pt) | 2007-03-23 | 2017-02-14 | Wyeth Llc | Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae |
| CN102307905B (zh) * | 2008-12-10 | 2015-11-25 | 斯克利普斯研究院 | 利用化学反应性非天然氨基酸产生载体-肽偶联物 |
| EP3017826A1 (en) | 2009-03-24 | 2016-05-11 | Novartis AG | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
| IT1398927B1 (it) * | 2009-06-25 | 2013-03-28 | Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi | Espressione batterica di un gene artificiale per la produzione di crm197 e derivati. |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| JP2011212183A (ja) | 2010-03-31 | 2011-10-27 | Terumo Corp | プレフィルドシリンジ |
| CN102807621B (zh) | 2011-06-01 | 2016-04-13 | 厦门大学 | 包含白喉毒素无毒突变体crm197或其片段的融合蛋白 |
| EP2776069A1 (en) | 2011-11-07 | 2014-09-17 | Novartis AG | Carrier molecule comprising a spr0096 and a spr2021 antigen |
| HRP20220455T1 (hr) | 2012-08-31 | 2022-05-27 | Sutro Biopharma, Inc. | Modificirane aminokiseline koje sadrže azid grupu |
| WO2014053521A2 (en) | 2012-10-02 | 2014-04-10 | Novartis Ag | Nonlinear saccharide conjugates |
| KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| WO2014102265A1 (en) * | 2012-12-27 | 2014-07-03 | Glycovaxyn Ag | Methods and compositions relating to crm197 |
| ITMI20130142A1 (it) * | 2013-01-31 | 2014-08-01 | Biosynth Srl | Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati |
| PL3055321T3 (pl) * | 2013-10-11 | 2019-02-28 | Sutro Biopharma, Inc. | SYNTETAZY tRNA DOŁĄCZAJĄCE AMINOKWAS NIENATURALNY DLA PARA-METYLOAZYDO-L-FENYLOALANINY |
| EP3055298B1 (en) | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| IL312327B2 (en) | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses |
| BR112016016580B1 (pt) | 2014-01-21 | 2024-01-09 | Pfizer Inc | Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina |
| CN120718167A (zh) | 2014-01-21 | 2025-09-30 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
| AU2015210674B2 (en) | 2014-01-31 | 2017-08-24 | Fina Biosolutions, Llc | Expression and purification of CRM197 and related proteins |
| AR101455A1 (es) * | 2014-08-05 | 2016-12-21 | Glaxosmithkline Biologicals Sa | Molécula portadora |
| EP4488286A3 (en) * | 2016-03-31 | 2025-04-02 | Pogona, Llc | Saccharide-polypeptide conjugate compositions and methods of use thereof |
| BR112019006278A2 (pt) * | 2016-09-30 | 2019-07-02 | Biological E Limited | composições de vacina pneumocócica multivalente que compreendem conjugados de polissacarídeo-proteína |
| ES3024474T3 (en) | 2016-12-30 | 2025-06-04 | Vaxcyte Inc | Polypeptide-antigen conjugates with non-natural amino acids |
-
2019
- 2019-07-01 CN CN201980044169.8A patent/CN112543649B/zh active Active
- 2019-07-01 IL IL279855A patent/IL279855B2/en unknown
- 2019-07-01 KR KR1020217003324A patent/KR20210042904A/ko active Pending
- 2019-07-01 EP EP19745001.8A patent/EP3817775B1/en active Active
- 2019-07-01 JP JP2021500060A patent/JP7399934B2/ja active Active
- 2019-07-01 EA EA202190168A patent/EA202190168A1/ru unknown
- 2019-07-01 ES ES19745001T patent/ES2989087T3/es active Active
- 2019-07-01 SG SG11202012905PA patent/SG11202012905PA/en unknown
- 2019-07-01 WO PCT/US2019/040131 patent/WO2020009993A1/en not_active Ceased
- 2019-07-01 AU AU2019299836A patent/AU2019299836B2/en active Active
- 2019-07-01 DK DK19745001.8T patent/DK3817775T3/da active
- 2019-07-01 BR BR112020026899-2A patent/BR112020026899A2/pt unknown
- 2019-07-01 CA CA3105361A patent/CA3105361A1/en active Pending
- 2019-07-01 MX MX2020014118A patent/MX2020014118A/es unknown
- 2019-07-01 EP EP24197275.1A patent/EP4483896A3/en active Pending
-
2020
- 2020-12-29 PH PH12020552282A patent/PH12020552282A1/en unknown
-
2021
- 2021-02-03 ZA ZA2021/00761A patent/ZA202100761B/en unknown
-
2023
- 2023-12-06 JP JP2023206041A patent/JP7796716B2/ja active Active
-
2025
- 2025-10-21 AU AU2025256067A patent/AU2025256067A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3817775B1 (en) | 2024-09-04 |
| CN112543649A (zh) | 2021-03-23 |
| JP7399934B2 (ja) | 2023-12-18 |
| KR20210042904A (ko) | 2021-04-20 |
| EP4483896A3 (en) | 2025-04-02 |
| IL279855A (en) | 2021-03-01 |
| JP2021530468A (ja) | 2021-11-11 |
| CN112543649B (zh) | 2026-03-31 |
| WO2020009993A1 (en) | 2020-01-09 |
| CA3105361A1 (en) | 2020-01-09 |
| EP4483896A2 (en) | 2025-01-01 |
| ES2989087T3 (es) | 2024-11-25 |
| SG11202012905PA (en) | 2021-01-28 |
| ZA202100761B (en) | 2025-05-28 |
| IL279855B1 (en) | 2025-09-01 |
| IL279855B2 (en) | 2026-01-01 |
| MX2020014118A (es) | 2021-06-18 |
| DK3817775T3 (da) | 2024-09-16 |
| AU2019299836B2 (en) | 2025-08-21 |
| EP3817775A1 (en) | 2021-05-12 |
| JP2024037805A (ja) | 2024-03-19 |
| EA202190168A1 (ru) | 2021-06-07 |
| AU2025256067A1 (en) | 2025-11-13 |
| BR112020026899A2 (pt) | 2021-03-30 |
| AU2019299836A1 (en) | 2021-02-25 |
| JP7796716B2 (ja) | 2026-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201903667B (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
| ZA202303901B (en) | Interleukin-2-fc fusion proteins and methods of use | |
| AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| MX337456B (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores. | |
| MX2021007368A (es) | Anticuerpos anti-receptor de transferrina y usos de los mismos. | |
| ZA202000027B (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
| MX2019008413A (es) | Celulas pluripotentes inmunodiseñadas. | |
| ZA202100761B (en) | Improvements in immunogenic conjugates | |
| PH12022551000A1 (en) | Directed conjugation technologies | |
| PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| MX2022011818A (es) | Metodos y composiciones para el direccionamiento de canceres de celulas t. | |
| MX2015005124A (es) | Conjugados de farmaco-proteina. | |
| UA103751C2 (ru) | Иммуногенный пептид для иммунотерапии | |
| EP4257186A3 (en) | Affinity medicant conjugates | |
| MX2016008355A (es) | Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. | |
| CY1115413T1 (el) | Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation | |
| WO2018187356A3 (en) | Protein antigens and uses thereof | |
| MX2018010247A (es) | Nuevos conjugados de amanitina. | |
| MY206284A (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| NZ612161A (en) | Radiolabled her2 binding peptides | |
| PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| NZ712148A (en) | Wt1 antigen peptide conjugate vaccine | |
| ZA202108534B (en) | Antibody drug conjugates |